Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $46 from $39 and keeps an Outperform rating on the shares. The firm cites the company’s recent positive pipeline updates for the target increase. The analyst added a new revenue contribution from Harmony’s gastro-resistant formulation of Wakix. It continues to favor the shares at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential
- Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences
- Harmony Biosciences announces results from pitolisant bioequivalence study
- Harmony Biosciences doses first patient in BP1.15205 trial
- Harmony Biosciences management to meet with Oppenheimer